Trump Touts Medicaid Drug Price Program Tied to Global Rates
President Trump promoted a program aligning Medicaid drug prices with those in other wealthy nations, claiming full state participation ahead of midterms.
President Trump publicly promoted a federal program designed to reduce prescription drug costs under Medicaid by benchmarking prices against those paid in other affluent countries, according to a report by The New York Times. The announcement came with an eye toward the approaching midterm elections, a period when healthcare affordability typically commands heightened voter attention.
Trump stated that all states had opted into the initiative, a claim that, if accurate, would represent an unusually broad and swift adoption of a federal drug pricing mechanism. The program's core approach — tying Medicaid reimbursement rates to international reference prices — mirrors a policy framework that has been debated in Washington for years but rarely implemented at scale.
Read more SEC Chair Atkins Moves to Scrap Shareholder Proposal Process →
Medicaid, the joint federal-state health insurance program serving tens of millions of low-income Americans, has long been a focal point in disputes over pharmaceutical pricing. Aligning its payments with those of peer nations such as those in Western Europe could, in principle, generate significant savings for both state governments and federal budgets, though the pharmaceutical industry has historically resisted such comparisons.
The timing of the announcement underscores the political salience of drug pricing as a campaign issue. Both parties have sought to demonstrate action on healthcare costs, and a program showing concrete, state-level buy-in could provide the administration with a visible policy achievement to highlight on the campaign trail.
Continue reading at NYT > Business for the full details and additional context on the program's scope and implications.
